4basebio (LSE:4BB), the Cambridge-based synthetic DNA specialist quoted on AIM, plans to raise gross proceeds of at least £15 million at 515 pence per share through a placing and subscription, plus up to £0.5 million from a retail offer. The plan needs shareholder approval and is not underwritten.
What 4basebio announced
At 07:00 on 15 October 2026, 4basebio announced "its intention to raise gross proceeds of not less than £15 million". The issue price of 515p is an 8.4% discount to the closing price of 562.5p on 14 October 2026, according to the announcement.
The capital raise comprises a proposed placing of 2,664,080 new ordinary shares through an accelerated bookbuild, a subscription for 1,025,239 new shares by certain directors and existing shareholders, and a retail offer of up to 97,087 new shares. The company said: "The Company and the Banks reserve the right to increase or decrease the gross proceeds to be raised under the placing." RBC Capital Markets is global coordinator, with Cavendish Capital Markets as joint bookrunner and Cairn Financial Advisers as nominated adviser.
Shareholder support and the loan offset
Several existing holders intend to take part. M&G, which holds 12.62%, intends to participate in the placing to maintain its stake. Elevage Medical Technologies, holding 17.16%, intends to subscribe for about £1.3 million, and directors Amy Walker, Heikki Lanckriet, Hansjörg Plaggemars and Richard Bungay intend to subscribe for 54,366 shares, about £0.3 million.
2Invest AG, part of the Deutsche Balaton group that holds 32.95%, will subscribe for 194,174 shares for about £1 million in cash and 776,699 shares for about £4 million settled by offsetting its shareholder loan. The €25 million loan will fall to a principal of €21,083,234 and its maturity will be extended by two years to 31 October 2030. The company said this is a related party transaction under the AIM Rules.
At 515p, the placing and subscription shares add up to about £19.0 million, of which about £4.0 million is the loan offset, leaving roughly £15.0 million in cash.
Why the raise matters
4basebio (LSE:4BB) makes synthetic DNA for genomic medicines and advanced therapies. Chief executive Dr Amy Walker said the company had seen steady interest and adoption of synthetic DNA across both scientific and clinical applications globally, resulting in significant growth in its client base and pipeline. The company said H1 2026 delivered a six-fold increase in its qualified pipeline.
The proceeds are for commercial development, aiming to "support targeted revenues of >£10 million per year driven by a pipeline of >£80 million". They will also fund the fit-out of the Q-Arc facility, R&D to cut turnaround times and improve yields, and working capital. The company said: "Following completion of the Capital Raise, the Company will have cash runway to H2 2028."
Risks for this AIM stock
The placing and subscription are not underwritten, and completion depends on shareholder approval. The new shares dilute holders who do not take part, and the revenue and pipeline figures are company targets rather than results. Hansjörg Plaggemars, a director and Managing Director of 2Invest AG, did not join the directors' fairness view on the related party element.
Key dates for UK shares watchers
The retail offer closes on 21 October 2026, and the general meeting is at 10am on 6 November 2026. Admission of the VCT placing shares is expected on 9 November, with the remaining new shares on 10 November. The company has agreed a 120-day lock-up after admission, subject to customary exceptions.
Where 4basebio goes from here
The bookbuild outcome, retail offer take-up and general meeting vote are the near-term steps. After that, progress on Q-Arc and turning pipeline into revenue are likely to shape views of the funding.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...